Thetis Pharmaceuticals

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Thetis is a biopharmaceutical company with platform technology developing first-in-class therapies for treatment of inflammatory diseases. Thetis’ drug candidates are based on a novel class of pro-resolving mediators (“Resolvins”) discovered by biomedical scientists at Harvard University. Their pioneering research has shown that Resolvins are potent agonists of inflammation resolution and tissue repair that can be delivered therapeutically to counteract an overactive immune response.

Thetis’ HEALER™ technology platform enables the development of Resolvins and other bioactive lipids new molecular entities with enhanced stability and bioavailability, overcoming key hurdles that have historically limited their development as pharmaceutical drugs. Thetis is leveraging this technology to develop a pipeline of non-immunosuppressive, small molecule therapies for treatment of pulmonary and gastrointestinal inflammatory disorders.
Company Type:
Company Website:
Company HQ State:
Connecticut
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Lead Product in Development:
TP-317 for acute respiratory distress syndrome (ARDS)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
Thetis Pharmaceuticals